Pharmaceuticals

Rising Bacterial Infections And The Surge In Demand For Carbapenem-Based Antibiotics Is A Driving Force In Market Expansion Is Supporting Development Across The Carbapenem-Based Antibiotics Market

May 18, 2026May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Carbapenem-Based Antibiotics Market Through 2030?

The carbapenem-based antibiotics market has experienced significant expansion recently. It is projected to increase from $4.78 billion in 2025 to $5.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. The market’s past growth can be attributed to the rising occurrence of bacterial infections, innovations in antibiotic formulations, increased understanding of nosocomial infections, an aging population, and the expansion of hospital networks.

The carbapenem-based antibiotics market is projected to experience substantial expansion over the upcoming years. It will grow to $6.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period is attributable to factors such as the rise of multidrug-resistant bacteria, advancements in combination therapies, broadening healthcare access in developing economies, the implementation of precision medicine strategies, and increased investment in new carbapenem derivatives. Key trends identified for the forecast period encompass escalating antibiotic resistance, a rise in hospital-acquired infections, the expansion of hospital infrastructure, an increase in surgical procedures, and a growing demand for antibiotics tailored for pediatric and geriatric patients.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What Key Growth Drivers Are Influencing The Carbapenem-Based Antibiotics Market?

The rising occurrence of bacterial infections is projected to stimulate the expansion of the carbapenem-based antibiotics market in the future. These infections stem from bacteria, which are microscopic organisms capable of entering the body and leading to various illnesses and symptoms. Carbapenem-based antibiotics are utilized to combat severe or multidrug-resistant bacterial infections, encompassing those caused by both gram-positive and gram-negative bacteria. An illustrative example comes from a July 2024 report by the US-based government agency, the Centers for Disease Control and Prevention, which indicated that in 2023, 78% of all bacterial infections in the historic catchment area were identified by CIDTs, with 46% exclusively diagnosed through CIDTs. Consequently, a heightened incidence of bacterial infections acts as a significant catalyst for the growth of the carbapenem-based antibiotics market.

How Is Segment Classification Applied In The Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

What Trends Are Influencing The Carbapenem-Based Antibiotics Market Outlook?

Leading companies in the carbapenem-based antibiotics market are introducing new financial and distribution models to sustain their market presence and bolster antibiotic stewardship. Subscription models are designed to delink revenue from the volume of sales, encouraging responsible consumption while ensuring profitability for pharmaceutical firms. For instance, in August 2024, the National Health Service (NHS), a UK-based government body, initiated a groundbreaking subscription scheme in collaboration with the pharmaceutical sector to combat antimicrobial resistance (AMR). This innovative framework enables drugmakers to receive fixed annual payments, up to $23.12 million (£20 million) per drug, regardless of prescription volume, thus removing any incentives for overuse. Valued at approximately £1.9 billion over 16 years, the initiative aims to stimulate the development of new antibiotics, including carbapenems, by ensuring financial viability for manufacturers. The NHS prioritizes products targeting critical pathogens identified by the World Health Organization, reinforcing its commitment to responsible antibiotic stewardship while fostering innovation in antibiotic development.

Which Companies Are Influencing The Carbapenem-Based Antibiotics Market?

Major companies operating in the carbapenem-based antibiotics market are Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, Teva Pharmaceutical Industries Ltd., Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co. Ltd., ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Access The Complete Carbapenem-Based Antibiotics Market Report:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

What Is The Largest Regional Market In The Carbapenem-Based Antibiotics Market?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Carbapenem-Based Antibiotics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

Browse Through More Reports Similar to the Global Carbapenem-Based Antibiotics Market 2026, By The Business Research Company

Carbapenem Based Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Macrolide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795